MARC LUSTGARTEN PANCREATIC CANCER … - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1998

Legal Domicile

Principal Officer

LINDA TANTAWI

Phone

5167371550

Tax Period

2024-07-01 to 2025-06-30

MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION, founded in 1998, is a mid-sized nonprofit in the Human Services sector that reported $37.2M in total revenue in fiscal year 2024. Revenue surged 63% from the prior year, signaling strong growth momentum. The organization ran a surplus of $10.0M, a strong 27% operating margin.

Mission

THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD. SEE SCHEDULE O.THE LUSTGARTEN FOUNDATION IS BOLDLY LEADING THE WAY THROUGH HOPE AND INNOVATION, TURNING FEAR INTO ACTION THROUGH EDUCATION AND EMPOWERMENT, AND ADVANCING THE BEST SCIENCE TO TRANSFORM PANCREATIC CANCER INTO A CURABLE DISEASE. THE FOUNDATION FOCUSES ON TRANSLATING OUR UNDERSTANDING OF THE UNDERLYING BIOLOGY OF PANCREATIC CANCER INTO CLINICAL APPLICATIONS TO CHANGE, EXTEND, AND ULTIMATELY SAVE PATIENTS' LIVES. IN FY25, THE FOUNDATION AWARDED $18 MILLION TO FUEL CUTTING-EDGE PANCREATIC CANCER RESEARCH, INCLUDING 10 NEW GRANTS TO RESEARCHERS AT SEVEN LEADING INSTITUTIONS. RESEARCH EFFORTS ARE CONCENTRATED ON THREE KEY PILLARS: EARLY DETECTION AND INTERCEPTION, DRUG DEVELOPMENT, AND PERSONALIZED MEDICINE.

Program Service Accomplishments

Program 1

Expenses: $19,810,727

RESEARCH PROGRAM: THE LUSTGARTEN FOUNDATION'S MISSION IS TO ADVANCE THE BEST SCIENCE TO TRANSFORM PANCREATIC CANCER INTO A CURABLE DISEASE. 2025 MARKED THE FOUNDATION'S 27TH YEAR OF DRIVING...

RESEARCH PROGRAM: THE LUSTGARTEN FOUNDATION'S MISSION IS TO ADVANCE THE BEST SCIENCE TO TRANSFORM PANCREATIC CANCER INTO A CURABLE DISEASE. 2025 MARKED THE FOUNDATION'S 27TH YEAR OF DRIVING PIONEERING PANCREATIC CANCER RESEARCH BREAKTHROUGHS, ACCELERATING PROGRESS FASTER THAN EVER BEFORE AND PROVIDING A MORE HOPEFUL FUTURE FOR ALL PATIENTS. SEE SCHEDULE O.

Program 2

Expenses: $1,235,976

PUBLIC EDUCATION AND INFORMATION PROGRAM: THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD, FUNDING PREEMINENT PANCREATIC CANCER RESEARCHERS, DRIVING THE PURSUIT OF BOLD AND INNOVATIVE SCIENCE TOWARD EARLIER DETECTION AND BETTER TREATMENTS, AND TRANSFORMING PANCREATIC CANCER INTO A CURABLE DISEASE. THE FOUNDATION FUNDS RESEARCH WHERE CREATIVE RISKS YIELD HIGH REWARDS TO ACCELERATE AND EXPAND LIFE-SAVING TREATMENT OPTIONS. WE BELIEVE TIME IS EVERYTHING TO PATIENTS AND THEIR FAMILIES, AND THAT COMMUNITY IS POWER. LUSTGARTEN PROGRAMS AND EVENTS PROVIDE PEOPLE AFFECTED BY PANCREATIC CANCER A VOICE AND A PLACE TO CREATE HOPE, TOGETHER. SEE SCHEDULE O.

Program 3

Expenses: $773,834

PROFESSIONAL EDUCATION PROGRAM: PROFESSIONAL EDUCATION FOCUSED ON THE FOUNDATION'S SCIENTIFIC LEADERSHIP CONDUCTING HIGH-LEVEL MEETINGS WITH FUNDED SCIENTISTS AND DIRECTORS OF THE LABS PROGRAM SITES AND COLLABORATING ORGANIZATIONS. ADDITIONALLY, THE LUSTGARTEN FOUNDATION PROVIDED SUPPORT FOR THE AACR SPECIAL CONFERENCE IN PANCREAS CANCER RESEARCH, AACR-LUSTGARTEN FOUNDATION-MARK FOUNDATION JOINT WORKSHOP ON SOLVING THE EARLY STAGE DIAGNOSIS FOR RALCITRANT CANCERS, THE GORDON RESEARCH CONFERENCE ON PANCREATIC DISEASES, THE INTERNATIONAL WOMEN'S DAY SYMPOSIUM AT THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, AND THE FOUNDATION'S SCIENTIFIC ADVISORY BOARD ANNUAL MEETING. SEE SCHEDULE O.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $34,677,585

Program Service Revenue $0

Investment Income $2,436,168

Other Revenue $76,957

TOTAL REVENUE $37,190,710

Expense Breakdown

Grants Paid $18,049,864

Salaries & Benefits $4,909,781

Fundraising Expenses $3,055,377

Program Expenses $21,820,537

Other Expenses $4,194,872

TOTAL EXPENSES $27,180,092

Year-over-Year Comparison

	2024	2023	Change
Revenue	$37,190,710	$22,749,028	+0.6%
Expenses	$27,180,092	$30,962,554	-0.1%
Net Income	$10,010,618	$-8,213,526	-2.2%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✓ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

1059

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$1,239,970

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
ANDREW LUSTGARTEN	CHAIRMAN	2.00	Officer Director	$0	$0	$0
ROBERT F VIZZA	CHAIRMAN EMERITUS	2.00	Officer Director	$0	$0	$0
JENNIE FORTUNOFF	SECRETARY	2.00	Officer Director	$0	$0	$0
PHILIP D'AMBROSIO	TREASURER	2.00	Officer Director	$0	$0	$0
ADAM SILVER	VICE CHAIRMAN	2.00	Officer Director	$0	$0	$0
SOMMER BAZURO PHD	DIRECTOR	2.00	Director	$0	$0	$0
JOHN H COBB	DIRECTOR	2.00	Director	$0	$0	$0
JESSICA LUSTGARTEN COURTEMANCHE	DIRECTOR	2.00	Director	$0	$0	$0
MARCIA LUSTGARTEN	DIRECTOR	2.00	Director	$0	$0	$0
SHEILA MAHONY	DIRECTOR	2.00	Director	$0	$0	$0
CHARLES R SCHUELER	DIRECTOR	2.00	Director	$0	$0	$0
WILLA SHALIT	DIRECTOR	2.00	Director	$0	$0	$0
SCOTT PENBERTHY	DIRECTOR	2.00	Director	$0	$0	$0
SELWYN VICKERS	DIRECTOR	2.00	Director	$0	$0	$0
AARON KANTOFF	DIRECTOR	2.00	Director	$0	$0	$0
RICHARD R BARAKAT MD MBA	DIRECTOR	2.00	Director	$0	$0	$0
LINDA TANTAWI	CEO	40.00	Officer	$489,273	$39,510	$528,783
KERRI KAPLAN	PRESIDENT	40.00	Officer	$341,967	$40,938	$382,905
FAISAL JAWAID	CFO	40.00	Officer	$287,237	$41,045	$328,282
ANDREW RAKEMAN	VP RESEARCH	40.00	Highest	$272,473	$41,720	$314,193
GLEN PECK	SVP TECHNOLOGY & BUSINESS INTELLIGENCE	40.00	Highest	$268,413	$39,490	$307,903
JACLYN P LYMAN	HEAD CLINICAL RESEARCH & DEVELOPMENT	40.00	Highest	$258,870	$21,280	$280,150
STEPHANIE DERGARABEDIAN	NATIONAL DIRECTOR OF DEVELOPMENT	40.00	Highest	$179,133	$35,668	$214,801
SUSAN M JACOBSON	DIRECTOR EXTERNAL & COMMUNITY RELATIONS	40.00	Highest	$166,081	$20,129	$186,210

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$37,190,710	$27,180,092	$91,535,774	$10,010,618
2024	$22,749,028	$30,962,554	$75,802,153	$-8,213,526
2023	$18,297,575	$28,681,699	$78,560,475	$-10,384,124
2022	$30,446,505	$33,834,657	$78,505,397	$-3,388,152
2021	$24,467,833	$21,726,029	$96,561,632	$2,741,804
2020	$14,966,634	$24,862,781	$90,551,380	$-9,896,147
2019	$29,500,163	$29,535,726	$99,323,748	$-35,563

MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION